Jiangsu Hengrui Surges 37% in Hong Kong Debut After $1.27B IPO

Jiangsu Hengrui Pharmaceuticals Co (HK:1276) made a powerful entrance on the Hong Kong Stock Exchange on Friday, with shares soaring over 37% in early trading after a $1.27 billion IPO. The offering was priced at HK$44.05—at the top of its range—reflecting strong investor appetite for the Chinese biopharmaceutical giant.

Shares opened at HK$57.10, marking a 29.6% jump from the offer price, and peaked at HK$60.20 shortly after the market opened. The robust debut highlights renewed investor confidence in Hong Kong’s IPO market, which has seen a notable resurgence, particularly from mainland Chinese companies pursuing dual listings.

Hengrui, already publicly traded in Shanghai, is one of China’s top drugmakers, specializing in oncology, innovative therapies, and biosimilars. The company plans to allocate IPO proceeds to accelerate clinical trials, scale production capabilities, and support global expansion. The strategic move is aimed at strengthening its international footprint and enhancing its competitiveness in the global pharmaceutical industry.

The timing of Hengrui’s successful listing coincides with the broader uptick in Hong Kong’s capital markets. Earlier this week, Contemporary Amperex Technology Co Ltd (CATL) (HK:3750) also debuted strongly, underscoring heightened interest in high-growth Chinese firms across sectors.

Jiangsu Hengrui’s performance signals positive momentum for biotech and pharmaceutical IPOs in Asia, particularly as global investors look toward companies with robust pipelines and innovation-driven strategies. With a clear focus on global growth and R&D, Hengrui's dual listing positions it to attract more institutional interest while reinforcing Hong Kong’s status as a hub for health tech and biotech capital.